Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2009. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding an increase in their personal holdings of Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on shareholding changes resulting from dividend reinvestment.
Material Changes
There are no material changes to the company's financial position reported in this document. The only reported activity is an increase in share ownership by specific individuals following the reinvestment of dividends paid on April 9, 2009.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Increase in Ordinary share holdings via dividend reinvestment.
- Share Price: Transactions occurred at a price of £10.09 per Ordinary share.
- Dividend Date: The dividend was paid to shareholders on April 9, 2009.
- Notified Parties: The filing details holdings for Mr. A P Witty, Mrs. C M Witty, Mr. J S Heslop, Mr. D Learmouth, Dr. D Pulman, and Mrs. C R Pulman.
- Notification Date: The company and named persons were advised of this information on April 16, 2009.